ArticlePLoS biology2023
Dynamics of SARS-CoV-2 infection hospitalisation and infection fatality ratios over 23 months in England.
Article in PLoS biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A Bayesian model for repeated cross-sectional epidemic prevalence survey data.PLoS computational biology · 2025Article
- Optimal pandemic control strategies and cost-effectiveness of COVID-19 non-pharmaceutical interventions in the United States.BMC global and public health · 2025Article
- Inferring temporal trends of multiple pathogens, variants, subtypes or serotypes from routine surveillance data.American journal of epidemiology · 2025Article
- Identifying COVID-19 peaks using early warning signals.PLoS computational biology · 2025Article
- The importance of playing the long game when it comes to pandemic surveillance.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Estimating Re and overdispersion in secondary cases from the size of identical sequence clusters of SARS-CoV-2.PLoS computational biology · 2025Article
- Biases in Routine Influenza Surveillance Indicators Used to Monitor Infection Incidence and Recommendations for Improvement.Influenza and other respiratory viruses · 2024Article
- The Impact of Healthcare Pressures on the COVID-19 Hospitalisation Fatality Risk in England.Journal of epidemiology and global health · 2024Observational
- Challenges in the case-based surveillance of infectious diseases.Royal Society open science · 2024Article
- Jointly estimating epidemiological dynamics of Covid-19 from case and wastewater data in Aotearoa New Zealand.Communications medicine · 2024Article
- Deviation from the recommended schedule: optimal dosing interval for a two-dose vaccination programme.Royal Society open science · 2024Article
- Key Challenges for Respiratory Virus Surveillance while Transitioning out of Acute Phase of COVID-19 Pandemic.Emerging infectious diseases · 2024Article
- Estimating SARS-CoV-2 infections and associated changes in COVID-19 severity and fatality.Influenza and other respiratory viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The relationship between prevalence of infection and severe outcomes such as hospitalisation and death changed over the course of the COVID-19 pandemic. Reliable estimates of the infection fatality ratio (IFR) and infection hospitalisation ratio (IHR) along with the time-delay between infection and hospitalisation/death can inform forecasts of the numbers/timing of severe outcomes and allow healthcare services to better prepare for periods of increased demand. The REal-time Assessment of Community Transmission-1 (REACT-1) study estimated swab positivity for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in England approximately monthly from May 2020 to March 2022. Here, we analyse the changing relationship between prevalence of swab positivity and the IFR and IHR over this period in England, using publicly available data for the daily number of deaths and hospitalisations, REACT-1 swab positivity data, time-delay models, and Bayesian P-spline models. We analyse data for all age groups together, as well as in 2 subgroups: those aged 65 and over and those aged 64 and under. Additionally, we analysed the relationship between swab positivity and daily case numbers to estimate the case ascertainment rate of England's mass testing programme. During 2020, we estimated the IFR to be 0.67% and the IHR to be 2.6%. By late 2021/early 2022, the IFR and IHR had both decreased to 0.097% and 0.76%, respectively. The average case ascertainment rate over the entire duration of the study was estimated to be 36.1%, but there was some significant variation in continuous estimates of the case ascertainment rate. Continuous estimates of the IFR and IHR of the virus were observed to increase during the periods of Alpha and Delta's emergence. During periods of vaccination rollout, and the emergence of the Omicron variant, the IFR and IHR decreased. During 2020, we estimated a time-lag of 19 days between hospitalisation and swab positivity, and 26 days between deaths and swab positivity. By late 2021/early 2022, these time-lags had decreased to 7 days for hospitalisations and 18 days for deaths. Even though many populations have high levels of immunity to SARS-CoV-2 from vaccination and natural infection, waning of immunity and variant emergence will continue to be an upwards pressure on the IHR and IFR. As investments in community surveillance of SARS-CoV-2 infection are scaled back, alternative methods are required to accurately track the ever-changing relationship between infection, hospitalisation, and death and hence provide vital information for healthcare provision and utilisation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.